Anja Charlotte Lundgren Mortensen

Anja Charlotte Lundgren Mortensen

Auto-generated profile, based on publicly available information

Anja Charlotte Lundgren Mortensen

Department of Immunology, Genetics and Pathology

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
AMAnja Charlotte Lundgren Mortensen
Anja Charlotte Lundgren Mortensen
HBHanna Berglund
Hanna Berglund
PJPreeti Jha
Preeti Jha
ASAdam Stenman
Adam Stenman
RSRam kumar selvaraju
Ram kumar selvaraju
MNMarika Nestor
Marika Nestor
Anaplastic thyroid cancer (ATC) is a rare but severe form of thyroid cancer responsible for approximately 50% of thyroid cancer deaths. Consequently, the identification of innovative therapies remains crucial for the effective treatment of ATC. Molecular radiotherapy is a rapidly growing field within oncology, and the cell surface antigen CD44v6, which is overexpressed in several cancers, is a plausible target for molecular radiotherapy of ATC. IHC of 39 patient samples with ATC was evaluated for CD44v6 expression. Biodistribution and dosimetry of iodine-125 (125I)–/lutetium-177 (177Lu)–labeled UU-40, a CD44v6-specific antibody, followed by in vivo efficacy in two ATC xenograft models with varying target expression levels (ACT-1 and BHT-101), accompanied by single-photon emission computed tomography (SPECT) imaging, evaluated radiolabeled UU-40 for therapeutic efficiency in ATC xenografts. The IHC revealed CD44v6 immunoreactivity in 46% of patient samples with ATC. The biodistribution favored 177Lu-labeled UU-40 over the 125I-labeled antibody and confirmed the in vivo specificity of both radioconjugates. The in vivo efficacy and accompanied SPECT imaging of a moderate CD44v6-expressing xenograft model (BHT-101) verified the tumor specificity, as well as the target-specific effect of 177Lu-labeled UU-40 on tumor growth and survival. A 100% complete response rate was demonstrated as a result of therapy using a single dose of 16 MBq 177Lu-labeled UU-40 in a high CD44v6-expressing xenograft model (ACT-1), and SPECT imaging revealed excellent tumor uptake of the radioconjugate at 14 days after injection. This study verifies the expression of CD44v6 in ATC and strengthens the superiority and promise of 177Lu-labeled UU-40 over 131I-labeled UU-40 for antibody-based molecular radiotherapy of CD44v6-positive ATC.

6 January 2026 in Nuclear Medicine Communications
Verified
Journal Article
Open access
MOMaryam Oroujeni
Maryam Oroujeni
RSRam Kumar Selvaraju
Ram Kumar Selvaraju
HPHelena Persson
Helena Persson
LDLeif Dahllund
Leif Dahllund
FFFredrik Y. Frejd
Fredrik Y. Frejd
AMAnja C.L. Mortensen
Anja C.L. Mortensen
Objective: Development of companion diagnostics for targeted radionuclide therapy is critical, especially for full-size antibodies with prolonged circulation times. Engineering antibodies to modify their in-vivo pharmacokinetics, such as incorporating neonatal Fc receptor (FcRn)-binding mutations, can potentially enable earlier imaging timing and improved patient stratification. This study aimed to evaluate the impact of FcRn-binding mutations on the in-vitro binding characteristics and in-vivo biodistribution and imaging performance of a CD44v6-targeting full-size antibody, UU-40, labeled with different radionuclides, and to assess its potential as a companion diagnostic. Methods: The study involved engineering UU-40 with LALA and IAHA mutations, evaluating specific binding, internalization, and affinity using in-vitro cell assays. Biodistribution and imaging studies [PET and single-photon emission computed tomography (SPECT)] were conducted in mice carrying human tumor xenografts in a dual-nuclide setting. Results: The FcRn mutations (LALA/IAHA) did not affect antibody specificity or affinity, which was target-specific and affinity remained in the subnanomolar range. Biodistribution studies demonstrated that the residualizing radiometal label ( 177 Lu) resulted in higher liver and spleen uptake compared with the nonresidualizing 125 I-label, leading to reduced tumor-to-organ ratios. Tumor uptake was higher in A431 xenografts, with peak accumulation at 24 h postinjection. SPECT and PET imaging confirmed superior contrast at later time points (~24 h) with 125 I-UU-40 LALA/IAHA , while earlier imaging with 68 Ga was hindered by increased nonspecific accumulation. Conclusion: FcRn-binding mutations in full-size antibodies significantly alter their in-vivo pharmacokinetics without affecting binding affinity or specificity. Introducing these mutations enables earlier imaging time points, enhancing the potential for companion diagnostics in clinical settings.

2 May 2025
Verified
Other
Open access
AMAnja Charlotte Lundgren Mortensen
Anja Charlotte Lundgren Mortensen
HBHanna Berglund
Hanna Berglund
PJPreeti Jha
Preeti Jha
ASAdam Stenman
Adam Stenman
RSRam kumar selvaraju
Ram kumar selvaraju
MNMarika Nestor
Marika Nestor
Supplemental Figure 4: Biodistribution of BHT-101 therapy mice. Left: Biodistribution of animals carrying BHT-101 xenografts treated with 177Lu-UU-40 (6.5 MBq) dissected on the day of termination due to reaching TBL. Right: Biodistribution of animals carrying BHT-101 xenografts treated with isotype control antibody, 177Lu-B1-8 (7 MBq), dissected on the day of termination due to reaching TBL.

2 May 2025
Verified
Other
Open access
AMAnja Charlotte Lundgren Mortensen
Anja Charlotte Lundgren Mortensen
HBHanna Berglund
Hanna Berglund
PJPreeti Jha
Preeti Jha
ASAdam Stenman
Adam Stenman
RSRam kumar selvaraju
Ram kumar selvaraju
MNMarika Nestor
Marika Nestor
Supplemental Figure 3: CD44v6 antigen expression levels of BHT-101 and ACT-1. A. In vitro specificity of 125I- and 177Lu-UU-40 with/without 100-fold molar excess (block) of unlabeled UU-40 on BHT-101 cells. B. In vitro specificity of 125I- and 177Lu-UU-40 with/without 100-fold molar excess (block) of unlabeled UU-40 on ACT-1 cells. C. IHC staining of CD44v6 in BHT-101 xenografts. D. IHC staining of CD44v6 in ACT-1 xenografts. Unpaired t-tests assessed the level of significance between blocked and unblocked wells of both radioconjugates on both cell lines. P < 0.0001 (****), p < 0.001 (***).

2 May 2025
Verified
Other
Open access
AMAnja Charlotte Lundgren Mortensen
Anja Charlotte Lundgren Mortensen
HBHanna Berglund
Hanna Berglund
PJPreeti Jha
Preeti Jha
ASAdam Stenman
Adam Stenman
RSRam kumar selvaraju
Ram kumar selvaraju
MNMarika Nestor
Marika Nestor
Supplemental Figure 1: Representative images of IHC-stainings for CD44v6 from tumors from ATC patients. Images were obtained by high resolution microscope using 400x magnification. No image-adjustments have been made. Case no T1-T39 are cross-linked with data found in Supplemental Table 1.

2 May 2025
Verified
Other
Open access
AMAnja Charlotte Lundgren Mortensen
Anja Charlotte Lundgren Mortensen
HBHanna Berglund
Hanna Berglund
PJPreeti Jha
Preeti Jha
ASAdam Stenman
Adam Stenman
RSRam kumar selvaraju
Ram kumar selvaraju
MNMarika Nestor
Marika Nestor
Anaplastic thyroid cancer (ATC) is a rare but severe form of thyroid cancer responsible for approximately 50% of thyroid cancer deaths. Consequently, the identification of innovative therapies remains crucial for the effective treatment of ATC. Molecular radiotherapy is a rapidly growing field within oncology, and the cell surface antigen CD44v6, which is overexpressed in several cancers, is a plausible target for molecular radiotherapy of ATC. IHC of 39 patient samples with ATC was evaluated for CD44v6 expression. Biodistribution and dosimetry of iodine-125 (125I)–/lutetium-177 (177Lu)–labeled UU-40, a CD44v6-specific antibody, followed by in vivo efficacy in two ATC xenograft models with varying target expression levels (ACT-1 and BHT-101), accompanied by single-photon emission computed tomography (SPECT) imaging, evaluated radiolabeled UU-40 for therapeutic efficiency in ATC xenografts. The IHC revealed CD44v6 immunoreactivity in 46% of patient samples with ATC. The biodistribution favored 177Lu-labeled UU-40 over the 125I-labeled antibody and confirmed the in vivo specificity of both radioconjugates. The in vivo efficacy and accompanied SPECT imaging of a moderate CD44v6-expressing xenograft model (BHT-101) verified the tumor specificity, as well as the target-specific effect of 177Lu-labeled UU-40 on tumor growth and survival. A 100% complete response rate was demonstrated as a result of therapy using a single dose of 16 MBq 177Lu-labeled UU-40 in a high CD44v6-expressing xenograft model (ACT-1), and SPECT imaging revealed excellent tumor uptake of the radioconjugate at 14 days after injection. This study verifies the expression of CD44v6 in ATC and strengthens the superiority and promise of 177Lu-labeled UU-40 over 131I-labeled UU-40 for antibody-based molecular radiotherapy of CD44v6-positive ATC.